Product Description
Mechanisms of Action: CXCR2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cystic Fibrosis|Colitis, Ulcerative
Phase 1: Chronic Obstructive Pulmonary Disease|Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00903201 | P2 |
Completed |
Cystic Fibrosis |
2010-12-29 |
|
2010-018738-27 | P2 |
Completed |
Cystic Fibrosis |
2010-12-29 |
|
CUC111342 | P2 |
Terminated |
Colitis, Ulcerative |
2009-12-12 |
|
2007-005520-32 | P2 |
Terminated |
Colitis, Ulcerative |
2009-10-01 |